Atreca IncOOTC BCEL Stock Report

Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 91 full-time employees. The company went IPO on 2019-06-20. The firm's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. The company has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models, including onemodel, in which PD-1 checkpoint inhibitors typically display limited activity. The firm commenced clinical development of ATRC-101 with a Phase Ib clinical trial.